Obagi Medical and Schweiger Dermatology Announce Collaboration for Obagi® saypha® MagIQ™

Partnership aims to generate real-world data on new injectable aesthetic product

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Obagi Medical, a skincare and aesthetics company, has announced a collaboration with Schweiger Dermatology, a leading national dermatology practice, for the ALOHA Program. The program will evaluate Obagi's new injectable product, Obagi® saypha® MagIQ™, through a Phase 4 clinical study and a real-world evaluation program across Schweiger's network of practices.

Why it matters

This partnership allows Obagi to gather robust clinical evidence and real-world insights on the performance of its new injectable product, which utilizes innovative technology to deliver natural-looking results. Schweiger's extensive network of dermatology practices and commitment to clinical excellence make them an ideal partner to help translate the product's clinical trial data into everyday practice.

The details

The ALOHA Program with Schweiger encompasses two initiatives: a Phase 4 clinical study led by Dr. David Goldberg at Schweiger's Hackensack location, and a real-world evaluation program that will give providers at select Schweiger aesthetic locations hands-on experience with the product and Obagi protocols. The goal is to drive patient satisfaction and strengthen provider-patient relationships.

  • The initial program activities are expected to begin in early 2026.
  • Schweiger will present initial findings at upcoming internal leadership meetings.
  • Results will also be presented at key industry conferences.

The players

Obagi Medical

A leading innovator in physician-dispensed skincare and aesthetic solutions, and part of Waldencast plc.

Schweiger Dermatology

A leading national dermatology practice, providing medical, cosmetic, and surgical dermatology, as well as allergy services.

Dr. David Goldberg

Director of Cosmetic Dermatology and Clinical Research at Schweiger Dermatology.

Drew Fine

U.S. General Manager, Professional Channel at Obagi Medical.

Obagi® saypha® MagIQ™

An injectable aesthetic product developed by Croma-Pharma GmbH, utilizing proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix.

Got photos? Submit your photos here. ›

What they’re saying

“This partnership with Obagi makes perfect sense for us. They're taking a thoughtful, evidence-based approach to introducing this innovative injectable, and we have the clinical depth and scale to evaluate how trial data translates into real-world outcomes across our diverse patient base.”

— Dr. David Goldberg, Director of Cosmetic Dermatology and Clinical Research at Schweiger Dermatology (Globe Newswire)

“Partnering with Schweiger Dermatology is a clear statement of our intent to launch this new injectable on a foundation of robust clinical evidence, education, and integrated patient outcomes.”

— Drew Fine, U.S. General Manager, Professional Channel at Obagi Medical (Globe Newswire)

What’s next

Initial program activities are expected to begin in early 2026, with Schweiger presenting initial findings at upcoming internal leadership meetings and key industry conferences.

The takeaway

This collaboration between Obagi Medical and Schweiger Dermatology demonstrates the importance of generating real-world evidence and integrating innovative products into comprehensive patient care protocols to drive positive outcomes and strengthen provider-patient relationships in the aesthetic dermatology field.